Skip to main content

Table 4 Baseline characteristics of participants by survival status in eastern Uganda

From: Treatment success and mortality among adults with tuberculosis in rural eastern Uganda: a retrospective cohort study

CharacteristicsLevelAlive
n = 906 (91.8%)
Died
n = 81 (8.2%)
p-value
DistrictSoroti418 (46.1)45 (55.6)0.027
Kumi213 (23.5)15 (18.5) 
Ngora125 (13.8)16 (19.8) 
Serere150 (16.6)5 (6.2) 
Level of health facilityHealth Center IV386 (42.6)22 (27.2)0.023
District Hospital182 (20.1)19 (23.5) 
Referral Hospital338 (37.3)40 (49.4) 
Location of health facilityRural252 (27.8)23 (28.4)1.000
Peri-urban654 (72.2)58 (71.6) 
Health facility ownershipPublic808 (89.2)72 (88.9)1.000
Private not for profit98 (10.8)9 (11.1) 
Year of TB treatment2015332 (36.6)35 (43.2)0.022
2016192 (21.2)25 (30.9) 
2017209 (23.1)14 (17.3) 
2018173 (19.1)7 (8.6) 
Age category (years)15–34436 (48.1)24 (29.6)0.002
35–50297 (32.8)31 (38.3) 
> 50173 (19.1)26 (32.1) 
Mean (SD)37.95 (15.05)44.80 (16.82)< 0.001
SexMale593 (65.5)58 (71.6)0.319
Female313 (34.5)23 (28.4) 
Persons with BC-PTBNew792 (87.4)70 (86.4)0.933
Previously treated114 (12.6)11 (13.6) 
Transfer inNo830 (91.6)73 (90.1)0.801
Yes76 (8.4)8 (9.9) 
Pre-therapy MTB load1+130 (14.3)12 (14.8)0.948
2+238 (26.3)20 (24.7) 
3+287 (31.7)28 (34.6) 
GeneXpert251 (27.7)21 (25.9) 
Drug regimen2RHZE/4RH560 (61.8)41 (50.6)0.136
2RHZE/6HE280 (30.9)33 (40.7) 
2RHZES/1RHZE/5RHE66 (7.3)7 (8.6) 
HIV statusNegative673 (74.3)31 (38.3)< 0.001
Positive233 (27.7)50 (61.7) 
Type of Directly Observed Therapy Short CourseHealth facility36 (4.0)9 (11.1)0.008
Community870 (96.0)72 (88.9) 
Treatment support availabilityNo111 (12.3)11 (13.6)0.864
Yes795 (87.7)70 (86.4) 
  1. Note: 1) 2RHZE/4RH: 2 months of Rifampicin (R), Isoniazid (H), Pyrazinamide (Z),Ethambutol / 4 months of RH; 2) 2RHZE/6EH: 2 months of RHZE)/ 6 months of EH; 3) 2RHZES/IRHZE/5RHE: 2 months of RHZE, Streptomycin/One month of RHZE/ 5 months of RHE; 4) MTB: Mycobacterium tuberculosis